CLINICAL VALUE OF THE PARAMETERS OF LOCAL AND REGIONAL VASCULAR RIGIDITY, WAYS FOR PHARMACOLOGICAL CORRECTION

Aim. To study the influence of age on the parameters of local vascular rigidity in healthy persons, and to assess correlations of carotid arteries rigidity in coronary heart disease (CHD) patients with arterial hypertension (AH)  of 1-2  grades   with assessment  of vasoprotective  effect  of a sartan — antagonist of angiotensin II receptors (AAR).

Material and methods. With an aim to study age and cardiovascular pathology  influence  on  the  parameters of local  rigidity, 44  healthy persons  included and 20 patients with AH of 1-2 grades  comorbid with proven  CHD. Local carotid  stiffness  was  assessed  by  ultrasound examination of carotid arteries, My Lab 90 device with the technology of radiofrequency analysis of vessel wall condition — echo tracking. Also, the influence was analyzed, of 24-week therapy by one of sartans  on structural and functional characteristics of carotid arteries.

Results. Comparison of the results of local stiffness in healthy group showed the local pulse wave velocity (PWV) in the range from 5,9±0,7 m/s  in those  30-39 year old to 6,6±1,1 m/s  in normotonics  >50 y.o., there  were  significant differences  in those  >50  y.o. comparing  with participants  <40 y.o. Analogical changes  were shown for the stiffness index β.  Together  with normalized  office blood  pressure (BP), AAR treatment  was  followed by a  decrease of local pressure in carotid arteries,  and decrease of carotid PWV from 9,9 (9,1; 11,5) m/s  to 8,3 (6,6; 8,6) m/s  with regression  by 17% (p<0,05).  Positive influence of AAR on structural and functional properties of carotid arteries confirms the significant growth of the coefficient by 3,3% (p<0,05), and decrease of stiffness  indexes  α &  β by 19,4% (р<0,05)  and  19,9% (p<0,01), respectively.

Conclusion. Parameters of local stiffness significantly correlated  with anthropometric parameters, duration of AH, systolic and diastolic BP in patients  with cardiovascular comorbidity. Therapy with sartan  followed by not only normalization of BP, but improved the parameters of local arterial rigidity.

1. Laurent S, Cockcroft L, Van Bortel, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-605.

2. Van Mieghem W. A multi-centre, double bind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension. J Hypertens 2001; 19 (suppl. 2): 152-6.

3. Boutouyrie P. New techniques for assessing arterial stiffness. Diabetes & Metabolism 2008; 34: 21-6.

4. DeLoach SS, Townsend RR. Vascular stiffness: Its Measurements and Significance for Epidemiologic and Outcome Studies. Clin J Am Soc Nephrol 2008; 3: 184-92.

5. Lyamina SV, Lyamina NP, Senchihin VN, et al. The endothelial biomarkers indicators of potential clinical course of hypertension in young patients. Hypertension 2010; 16 (3): 261-5. Russian (Лямина С. В., Лямина Н. П., Сенчихин В. Н. и др. Эндотелиальные биомаркеры — потенциальные индикаторы клинического течения артериальной гипертонии у пациентов молодого возраста). Артериальная гипертензия 2010; 16 (3): 261-5).

6. Melnikova EA, Avdeevа IV, Oleynikov VE. Ehotreking — a new technology assessment of structural and functional properties of the carotid artery bed (review). Modern Technologies in Medicine 2016; 8 (2): 119-29. Russian (Мельникова Е. А. Авдее ва И. В. Олейников В. Э. Эхотрекинг — новая технология оценки структурно-функциональных свойств артерий каротидного русла (обзор). Современные технологии в медицине 2016; 8(2): 119-29).

7. Mattace-Raso FU, Cammen TJ, Hofman A, et al. Arterial stiffness and risk of corornary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113: 657-63.

8. Owens DS, Katz R, Takasu J, et al. Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA). Am J Cardiol 2010; 105(5): 701-8.

9. Riley WA, Evans GW, Sharrett AR, et al. Variation of common carotid artery elasticity with intimal-medial thickness: the ARIC Study. Atherosclerosis Risk in Communities. Ultrasound Med Biol 1997; 23: 157-64 [PubMed: 9140173].

10. Matsui Y Eguchi K, Michael O'Rourke, et al. Differential Effects Between a Calcium Channel Blocker and Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients. Hypertension 2009; 54: 716-23.

11. Smith RD, Yokoyama H, Averill DB, et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006; 6(5): 335-42.

12. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives. J Hypertens 2001; 19 (Suppl. 1): S